Marty Makary's departure from the Food and Drug Administration may remove one of the Trump administration's lightning rods for controversy.

But it won't solve the organizational upheaval and political jockeying that marked much of his 13-month tenure.

Why it matters: There's lots of uncertainty around how the Senate will find the bandwidth to confirm another FDA commissioner while it considers President Trump's nominees for Centers for Disease Control and Prevention director and surgeon general .

The FDA itself is also facing other key internal vacancies, including for directors of the centers overseeing drugs and biologics.

And there are questions about whether a successor will continue efforts to streamline clinical trials and other regulatory actions.

Driving the news: On Tuesday, Trump confirmed Makary was out after facing internal criticism for not accommodating some of the president's priorities, as well as complaints from health care investors about unpredictable regulatory decisions that…